Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis

This study has been completed.
Sponsor:
Information provided by:
Hamamatsu University
ClinicalTrials.gov Identifier:
NCT00457561
First received: April 5, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
  Purpose
Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin levels, may be associated with requirements for higher recombinant human erythropoietin doses and a subsequent worse prognosis in patients beginning hemodialysis.

Condition
Hemodialysis

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Hamamatsu University:

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patients who started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis centers in the Shizuoka prefecture area, and who survived for more than 3 months after the start of hemodialysis.

Exclusion Criteria:

  • Nothing particular.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00457561

Sponsors and Collaborators
Hamamatsu University
Investigators
Principal Investigator: Naro Ohashi, MD,PhD First Department of Medicine, Hamamatsu University School of Medicine
  More Information

ClinicalTrials.gov Identifier: NCT00457561     History of Changes
Other Study ID Numbers: 19710808 
Study First Received: April 5, 2007
Last Updated: April 5, 2007
Health Authority: Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Hamamatsu University:
The relationship between all-cause mortality in patients introduced hemodialysis and recombinant human erythropoietin dose and serum adiponectin level

Additional relevant MeSH terms:
Epoetin Alfa
Hematinics

ClinicalTrials.gov processed this record on December 02, 2016